KOR
ENG

Global Leader of Cancer Treatment

Innovative new drugs
available to cancer patients

Making Innovative New Drug available to patients

Global Leader of Cancer Treatment

Innovative new drugs
available to cancer patients

ASO new drugs are presented by innovative oligonucleotide designs through informatics technology ASODE+ and CATs platform.

Global Leader of Cancer Treatment

Innovative new drugs
available to cancer patients

Next generation small molecule new drugs can significantly reduce side effects of existing medications.

Autotelic Bio’s Science

ASO therapeutics can inhibit the production of target disease proteins and can fundamentally block disease-expressing genes.

Autotelic Bio’s R&D Pipeline

We have 4 assets under development: 3 for ASO anti-cancer drugs and 1 for small molecule new drugs.

ATB-101

World’s 1st Diabetes + Hypertension Fixed Dose Combination

ATB-301

TGF-β2 Targeting ASO (Combination Therapy with IL-2)

ATB-320

Next Generation ASO

ATB-350

Selective KRAS G12V Mutation Targeting ASO

ATB-610

Inhalant Small Molecule IPF Treatment

Privacy Policy
Headquarter.#302, 194-41, Osong-saengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 28610, Republic of Korea
R&D Center.#510 Signature Gwanggyo Knowledge Business Center 37, Poeun-daero 59beon-gil, Suji-gu, Yongin-si, Gyeonggi-do, 16864, Republic of Korea
- T.043-233-9373
- F.043-233-9374
- E.info@autotelic.co.kr

Copyright @AUTOTELIC. All rights reserved.